# AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

> **NCT05617755** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Arsenal Biosciences, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma, Ovarian Epithelial
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Neoplasms, Glandular and Epithelial
- Ovarian Diseases
- Genital Neoplasm, Female
- Abdominal Neoplasm
- Recurrence

## Interventions

- **BIOLOGICAL:** AB-1015

## Key facts

- **NCT ID:** NCT05617755
- **Lead sponsor:** Arsenal Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-29
- **Primary completion:** 2024-09-30
- **Final completion:** 2027-02
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617755, "AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05617755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*